Renovo, plc.

Revision as of 14:25, 6 September 2012 by WikiBot (talk | contribs) (Robot: Automated text replacement (-{{reflist}} +{{reflist|2}}, -<references /> +{{reflist|2}}, -{{WikiDoc Cardiology Network Infobox}} +))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Template:Infobox Company

Renovo, plc. (Template:Lse) is a biopharmaceutical company based in Manchester, UK. It is the world leader in scar prevention and reduction research[1], and it aims "to be first to market with a scar prevention pharmaceutical drug in the US and Europe"[2] in 2009.

The US commercial market for prevention and reduction of scarring in the skin is valued at approximately US$4 billion per annum, and the market is larger in patient volume than Depression, Osteoporosis, Asthma and Diabetes[3].

Products

Currently the company doesn't have a marketed product, though its pipeline includes one drug that has recently initiated phase III clinical development, three drugs in phase II clinical development, and 13 other pre-clinical candidates.

Drug Phase Action
Juvista Phase III Clinical trial scar prevention, also for vascular restenosis
Juvidex Phase II Clinical trial scar reduction, also for abdominal adhesions and eye scars
Prevascar Phase II Clinical trial scar prevention, also for nerves and eyes
Zesteem Phase II Clinical trial acute skin healing

References

External links

Template:Med-company-stub